GILD
stock Healthcare Drug Manufacturers - GeneralOverall Healthy · 74%
- Fundamentals Strong
- Trajectory Climbing
- Leadership Churning
A read across fundamentals, recent price & growth trajectory, and leadership stability. For fun and reading at a glance, not investment advice.
What the indicators say
Mixed 2 of 5 trend signals bullishRSI 42 — soft momentum, not yet oversold.
A mechanical reading of the chart’s indicators — not investment advice.
Key statsas of Jun 3
- Open
- $128.99
- +1.11%
- Close
- $128.99
- +1.11%
- Current
- $128.99
- Prev close
- $127.57
- Today
- 5.98M
- 3-mo avg
- 6.14M
Earningscalendar synced from Yahoo 57d ago
- Most recent
- May 775 days ago
- Next expected
- Aug 6in 16 days
Recent earnings dates
- May 7 75 days ago
- Feb 10 161 days ago
- Oct 30, 2025 264 days ago
- Aug 7, 2025 348 days ago
Past earnings dates come from GILD’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.
Fundamentalssynced from SEC 53d ago
Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), GILD’s fundamentals read as strong overall.
At 17.5x, the price is a reasonable multiple of the company's annual profit.
Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.
A 2.4% yield is a healthy, generally sustainable level of cash income.
The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.
A 28.9% margin is strong; the company keeps a healthy slice of every revenue dollar.
The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.
A 37.5% return on equity is strong; the company compounds owners' capital well.
Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.
A 14.4% return on assets is strong; the company squeezes good profit from its assets.
Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.
Not enough data to compute debt-to-equity.
Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.
At 1.55, short-term assets comfortably cover short-term bills.
Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.
Revenue grew 2.4% from the prior year: steady, modest expansion.
Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.
Net income grew 1672.9% from the prior year: strong profit expansion.
Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.
Financialssynced from SEC 53d ago
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B |
| Net income | $6.2B | $4.6B | $5.7B | $480.0M | $8.5B |
| Diluted EPS | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |
| Dividend / share | $2.84 | $2.92 | $3.00 | $3.08 | $3.16 |
| Total assets | $68.0B | $63.2B | $62.1B | $59.0B | $59.0B |
| Total liabilities | — | — | — | — | — |
| Shareholder equity | $21.1B | $21.2B | $22.7B | $19.3B | $22.7B |
| Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.0B | $7.5B | $7.6B | $6.7B | $7.1B | $7.8B | $7.9B | $7.0B |
| Net income | $1.6B | $1.3B | $1.8B | $1.3B | $2.0B | $3.1B | $2.2B | $2.0B |
| Diluted EPS | $1.29 | $1.00 | $1.43 | $1.04 | $1.56 | $2.43 | $1.75 | $1.61 |
| Dividend / share | $0.77 | $0.77 | $0.77 | $0.79 | $0.79 | $0.79 | $0.79 | $0.82 |
Leadershipsynced from SEC 59d ago
- O'Day Daniel Patrick Chairman & CEO · Director
- Dickinson Andrew D Chief Financial Officer
- Berger Dietmar Chief Medical Officer
- Burkhart Erin SVP, Controllership
- Cain Wettan Keeley M EVP Gen Counsel, Legal & Comp
- Mercier Johanna Chief Comm & Corp Aff Officer
- Barton Jacqueline K Director
- Bluestone Jeffrey Director
- Horning Sandra Director
- Kramer Kelly A. Director
- Love Ted W Director
- Manwani Harish Director
- Rodriguez Javier Director
- Welters Anthony Director
Officers and board are drawn from GILD’s recent SEC ownership filings (Forms 3, 4 and 5).
Notable recent eventspast year
- Feb 11 +5.8% one-day move
- Dec 31, 2025 FY2025 net income +1673% YoY
- Nov 19, 2025 Officer or director change reported in an 8-K
- Aug 14, 2025 Officer or director change reported in an 8-K
- Aug 8, 2025 +8.3% one-day move
Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.
Dividendssynced from Yahoo 52d ago
- 2025 total
- $3.16
- 2026 so far
- $0.821 payment
- 2026 projected
- $3.28+3.8% vs 2025
Projection scales GILD’s declared payments so far this year up to the inferred cadence, then compares to last year’s total. Between payouts it is an estimate, not a guarantee.
Payment history
- Mar 13 $0.82
- Dec 15, 2025 $0.79
- Sep 15, 2025 $0.79
- Jun 13, 2025 $0.79
- Mar 14, 2025 $0.79
- Dec 13, 2024 $0.77
- Sep 13, 2024 $0.77
- Jun 14, 2024 $0.77
- Mar 14, 2024 $0.77
- Dec 14, 2023 $0.75
- Sep 14, 2023 $0.75
- Jun 14, 2023 $0.75
- Mar 14, 2023 $0.75
- Dec 14, 2022 $0.73
- Sep 14, 2022 $0.73
- Jun 14, 2022 $0.73
- Mar 14, 2022 $0.73
- Dec 14, 2021 $0.71
- Sep 14, 2021 $0.71
- Jun 14, 2021 $0.71
Recent SEC filingssynced from SEC 53d ago
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- DEF 14A Proxy statement
- 10-K Annual report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report